Toxicity testing of the VEGF inhibitors bevacizumab, ranibizumab and pegaptanib in rats both with and without prior retinal ganglion cell damage

Acta Ophthalmologica

Volumn 88, Issue 5, 2010, Pages

  Thaler, Sebastian ^a   Fiedorowicz, Michal ^a,b   Choragiewicz, Tomasz J ^a,c   Bolz, Sylvia ^a   Tura, Ayseguel ^d   Henke Fahle, Sigrid ^a   Yoeruek, Efdal ^a   Zrenner, Eberhart ^a   Bartz Schmidt, Karl Ulrich ^a   Ziemssen, Focke ^a   Schuettauf, Frank ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

anti VEGF; bevacizumab; pegaptanib; ranibizumab; retinal ganglion cells

Indexed keywords

BEVACIZUMAB; N METHYL DEXTRO ASPARTIC ACID; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CELL DAMAGE; CELL SWELLING; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; IN VIVO STUDY; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; TOXICITY TESTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; CELL COUNT; EXCITATORY AMINO ACID AGONISTS; FEMALE; INJECTIONS; MITOCHONDRIA; N-METHYLASPARTATE; RATS; RATS, INBRED BN; RETINAL GANGLION CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77954629812     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/j.1755-3768.2010.01927.x     Document Type: Article

References (41)

1. Astam N, Batioglu F Ozmert E (2009 Short-term efficacy of intravitreal bevacizumab for the treatment of macular edema due to diabetic retinopathy and retinal vein occlusion. Int Ophthalmol 29 : 343 348.
2. Barber AJ (2003 A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27 : 283 290.
3. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG Gardner TW (1998 Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102 : 783 791.
4. Beutel J, Peters S, Luke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E Grisanti S (2010 Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 88 : 103 109.
5. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, Paschke M, Zahn G Cursiefen C (2007 Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48 : 2545 2552.
6. Cheng CK, Peng PH, Tien LT, Cai YJ, Chen CF Lee YJ (2009 Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection. Retina 29 : 306 312.
7. Dong CJ, Guo Y, Agey P, Wheeler L Hare WA (2008 α2 adrenergic modulation of NMDA receptor function as a major mechanism of retinal ganglion cell protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 49 : 4515 4522.
8. Fang X, Sakaguchi H, Gomi F et al. (2008 Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. Acta Ophthalmol 86 : 800 805.
9. Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y Hartnett ME (2008 Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis 14 : 345 357.
10. Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G Bautch VL (2008 Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci 49 : 3107 3114.
11. Heiduschka P, Julien S, Hofmeister S, Bartz-Schmidt KU Schraermeyer U (2008 Bevacizumab (avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28 : 46 55.
12. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R Temel SG (2007 Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48 : 1773 1781.
13. Iriyama A, Uchida S, Yanagi Y, Tamaki Y, Inoue Y, Matsuura K, Kadonosono K Araie M (2004 Effects of indocyanine green on retinal ganglion cells. Invest Ophthalmol Vis Sci 45 : 943 947.
14. Iriyama A, Chen YN, Tamaki Y Yanagi Y (2007 Effect of anti-VEGF antibody on retinal ganglion cells in rats. Br J Ophthalmol 91 : 1230 1233.
15. Jin KL, Mao XO Greenberg DA (2000 Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 97 : 10242 10247.
16. Kilic U, Kilic E, Jarve A et al. (2006 Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways. J Neurosci 26 : 12439 12446.
17. Kim SY, Sadda S, Pearlman J, Humayun MS, de Juan E Jr., Melia BM Green WR (2002 Morphometric analysis of the macula in eyes with disciform age-related macular degeneration. Retina 22 : 471 477. (Pubitemid 35025524)
18. Lam TT, Abler AS, Kwong JM Tso MO (1999 N-methyl-D-aspartate (NMDA)-induced apoptosis in rat retina. Invest Ophthalmol Vis Sci 40 : 2391 2397.
19. Lambrechts D Carmeliet P (2006 VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 1762 : 1109 1121.
20. Levkovitch-Verbin H, Quigley HA, Martin KR, Zack DJ, Pease ME Valenta DF (2003 A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci 44 : 3388 3393.
21. Lopes de Faria JM, Russ H Costa VP (2002 Retinal nerve fibre layer loss in patients with type 1 diabetes mellitus without retinopathy. Br J Ophthalmol 86 : 725 728.
22. Lu F Adelman RA (2009 Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol 247 : 171 177.
23. Manzano RP, Peyman GA, Khan P Kivilcim M (2006 Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26 : 257 261.
24. Manzano RP, Peyman GA, Khan P, Carvounis PE, Kivilcim M, Ren M, Lake JC Chevez-Barrios P (2007 Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 91 : 804 807.
25. Medeiros NE Curcio CA (2001 Preservation of ganglion cell layer neurons in age-related macular degeneration. Invest Ophthalmol Vis Sci 42 : 795 803.
26. Meyer-Rusenberg B, Pavlidis M, Stupp T Thanos S (2007 Pathological changes in human retinal ganglion cells associated with diabetic and hypertensive retinopathy. Graefes Arch Clin Exp Ophthalmol 245 : 1009 1018.
27. Nakazawa T, Shimura M, Endo S, Takahashi H, Mori N Tamai M (2005 N-Methyl-D-Aspartic acid suppresses Akt activity through protein phosphatase in retinal ganglion cells. Mol Vis 11 : 1173 1182.
28. Nishijima K, Ng YS, Zhong L et al. (2007 Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171 : 53 67.
29. Poesen K, Janssens T, Lambrechts D, Carmeliet P Conway EM (2008 Advantages of the Vegf inhibitor, macugen: a more favourable toxicity profile. Invest Ophthalmol Vis Sci 49 : E-Abstract 3412.
30. Rosenfeld PJ, Fung AE Puliafito CA (2005 Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36 : 336 339.
31. Rothman SM Olney JW (1986 Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 19 : 105 111.
32. Santiago AR, Hughes JM, Kamphuis W, Schlingemann RO Ambrosio AF (2008 Diabetes changes ionotropic glutamate receptor subunit expression level in the human retina. Brain Res 1198 : 153 159.
33. Shima C, Sakaguchi H, Gomi F et al. (2008 Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 86 : 372 376.
34. Shimomura Y, Hirata A, Ishikawa S Okinami S (2009 Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection. Graefes Arch Clin Exp Ophthalmol 247 : 1089 1094.
35. Tezel G, Yang X Cai J (2005 Proteomic identification of oxidatively modified retinal proteins in a chronic pressure-induced rat model of glaucoma. Invest Ophthalmol Vis Sci 46 : 3177 3187.
36. Thaler S, Rejdak R, Dietrich K et al. (2006 A selective method for transfection of retinal ganglion cells by retrograde transfer of antisense oligonucleotides against kynurenine aminotransferase II. Mol Vis 12 : 100 107.
37. Thaler S, Haritoglou C, Choragiewicz TJ et al. (2008 In vivo toxicity study of rhodamine 6G in the rat retina. Invest Ophthalmol Vis Sci 49 : 2120 2126.
38. Vorwerk CK, Naskar R, Schuettauf F, Zurakowski D, McDermott LM, Quinto KM Dreyer EB (2001 Excitotoxicity can be mediated through an interaction within the optic nerve; activation of cell body NMDA receptors is not required. Vet Ophthalmol 4 : 201 204.
39. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, Marti HH Hermann DM (2005 VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128 : 52 63.
40. Yandiev Y, Francke M, Reichenbach A, Wiedemann P, Bringmann A Uhlmann S (2008 Intravitreal Avastin Does Not Induce Pathological Changes in the Pig Retina. ARVO Meeting Abstracts 49 : 5580.
41. Yu L, Wu X, Cheng Z et al. (2008 Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 49 : 522 527.